Development of fluorophore labeled or biotinylated anticancer small molecule NSC243928

Area of Science:

• Biochemistry
• Molecular Biology
• Medicinal Chemistry

Background:

• Triple-negative breast cancer (TNBC) remains a challenging malignancy with limited targeted treatment options.
• LY6K is identified as a potential therapeutic target in TNBC and other cancers.
• The small molecule NSC243928 shows promise in inducing cancer cell death via LY6K interaction, but its mechanism is not fully understood.

Purpose of the Study:

• To develop novel chemical tools for elucidating the molecular mechanisms underlying the interaction between NSC243928 and LY6K.
• To synthesize and characterize biotinylated and fluorophore-tethered derivatives of NSC243928.
• To validate the binding affinity and cellular retention of these derivatives in LY6K-expressing cancer cells.

Main Methods:

• Computational studies including molecular docking and dynamics simulations guided the design of NSC243928 derivatives.
• Chemical synthesis was employed to create biotinylated and NBD-fluorophore-tethered analogs of NSC243928.
• Surface plasmon resonance (SPR) assays were used to confirm direct binding of derivatives to LY6K protein.
• Confocal microscopy was utilized to assess the cellular localization and retention of the NBD-tagged derivative in LY6K-expressing cancer cells.

Main Results:

• Docking studies and molecular dynamics simulations informed the rational design of modified NSC243928 compounds.
• Synthesized biotinylated and NBD-fluorophore-tethered NSC243928 derivatives demonstrated retained direct binding to LY6K protein, confirmed by SPR.
• Confocal analysis showed that the NBD-tagged NSC243928 derivative is effectively retained within LY6K-expressing cancer cells.

Conclusions:

• Novel chemical tools, including biotinylated and NBD-fluorophore-tethered NSC243928 derivatives, have been successfully developed and synthesized.
• These derivatives maintain direct binding to LY6K and exhibit cellular retention, validating their utility for mechanistic studies.
• These compounds represent valuable tools for future in vitro and in vivo investigations into NSC243928's mechanism of action and potential therapeutic applications in LY6K-expressing cancers, including TNBC.